Encouragingly, it was recently shown that a single residue mutation within the APP gene which reduces the ability of β-secretase to cleave APP confers a strongly protective effect against both AD and general cognitive decline in a human population [118], which many have taken as further support of the amyloid hypothesis and of BACE1 as a therapeutic target in AD. This evidence concerns the gene APP and Mental deterioration.